Cara hauls in $70M on first leg of global deal, setting up PhIII kidney disease drug for commercial roll out
Cara Pharmaceuticals, a small biotech in Connecticut, is licensing out its late-stage kidney disease drug in a deal that gives a Swiss pharmaceutical company commercialization …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
